.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

LATISSE Drug Profile

« Back to Dashboard
Latisse is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in ten countries.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the bimatoprost profile page.

Summary for Tradename: LATISSE

Patents:13
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: LATISSE

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog

Clinical Trials for: LATISSE

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008RXYes8,906,962Jan 31, 2021
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008RXYes8,758,733Jan 15, 2023
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008RXYes9,216,183Jan 15, 2023
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LATISSE

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 20086,403,649<disabled>
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 20088,017,655<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LATISSE

Drugname Dosage Strength RLD Submissiondate
bimatoprosTopical Solution0.03%Latisse5/3/2010

Non-Orange Book Patents for Tradename: LATISSE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,298,518Method of enhancing hair growth<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LATISSE

Country Document Number Estimated Expiration
European Patent Office2250996<disabled in preview>
Canada2401731<disabled in preview>
World Intellectual Property Organization (WIPO)03066008<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LATISSE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00099Netherlands<disabled>PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C0033France<disabled>PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
C/GB02/035United Kingdom<disabled>PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc